Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous anti-CDH17 CAR-T cells CHM-2101

A preparation of autologous T lymphocytes transduced with a lentiviral vector expressing a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) cadherin-17 (CDH17), with potential immunomodulatory and antineoplastic activities. After isolation, transduction, and expansion in culture, the autologous anti-CDH17 CAR-T cells CHM-2101 are reintroduced into the patient and are directed to tumor cells expressing CDH17, which may result in a selective toxicity against, and lysis of CDH17-expressing tumor cells. CDH17, a cell surface adhesion protein, is overexpressed in a variety of cancer cell types.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous anti-cadherin-17 CAR-T cells CHM-2101
autologous anti-CDH17 CAR T cells CHM-2101
CDH17 CAR T cells CHM-2101
Code name:CHM 2101
CHM-2101
CHM2101
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search